A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

This is a phase I/II trial of SHB-02-CD19, T-cell expressing an anti-CD19 Chimeric-Antigen-Receptor (CAR) in patients with CD19 expressing B-cell malignancies. This trial is an open label, single-arm, for pediatric and adult patients with relapsed/refractory B-cell malignancies.

NCT Number	NCT07503353
Lead Sponsor	Sheba Medical Center
Conditions	B Cell Malignancies, Acute Lymphobkastic Leukemia, Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Enrollment	50 participants
Start Date	2026-06
Primary Completion	2029-06 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-31